

# Biologics for Autoimmune Diseases

## Goal(s):

- Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use.
- Promote use that is consistent with national clinical practice guidelines and medical evidence.
- Promote use of high value products.

## Length of Authorization:

- Up to 12 months

## Requires PA:

- All biologics for autoimmune diseases (both pharmacy and physician-administered claims)

## Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at [www.orpdl.org](http://www.orpdl.org)
- Searchable site for Oregon FFS Drug Class listed at [www.orpdl.org/drugs/](http://www.orpdl.org/drugs/)

**Table 1.** Approved and Funded Indications for Biologic Immunosuppressants.

Drug Name	Ankylosing Spondylitis	Crohn's Disease	Juvenile Idiopathic Arthritis	Plaque Psoriasis	Psoriatic Arthritis	Rheumatoid Arthritis	Ulcerative Colitis	Other
Abatacept (ORENCIA)			≥2 yo		≥18 yo	≥18 yo		
Adalimumab (HUMIRA) and biosimilars	≥18 yo	≥6 yo (Humira) ≥18 yo (biosimilars)	≥2 yo (Humira) ≥4 yo (biosimilars)	≥18 yo	≥18 yo	≥18 yo	≥18 yo	Uveitis (non-infectious) ≥2 yo (Humira)
Anakinra (KINERET)						≥18 yo		NOMID
Apremilast (OTEZLA)				≥18 yo	≥18 yo			
Baricitinib (OLUMIANT)						≥18 yo		
Broadalumab (SILIQ)				≥18 yo				
Canakinumab (ILARIS)			≥2 yo					FCAS ≥4 yo MWS ≥4 yo TRAPS ≥4yo HIDS ≥4 yo MKD ≥4 yo FMF ≥4 yo
Certolizumab (CIMZIA)	≥18 yo	≥18 yo		≥18 yo	≥18 yo	≥18 yo		
Etanercept (ENBREL) and biosimilars	≥18 yo		≥2 yo	≥4 yo (Enbrel) ≥18 yo (biosimilars)	≥18 yo	≥18 yo		
Golimumab (SIMPONI and SIMPONI ARIA)	≥18 yo				≥18 yo	≥18 yo	≥18 yo (Simponi)	
Guselkumab (Tremfya)				≥18 yo				
Infliximab (REMICADE) and biosimilars	≥18 yo	≥6 yo		≥18 yo	≥18 yo	≥18 yo	≥6 yo (Remicade & biosimilars)	
Ixekizumab (TALTZ)				≥18 yo	≥18 yo			
Rituximab (RITUXAN)						≥18 yo		CLL ≥18 yo NHL ≥18 yo GPA ≥18 yo

								Pemphigus Vulgaris ≥18 yo
Risankizumab-rzaa (SKYRIZI)				≥18 yo				
Sarilumab (KEVZARA)						≥18 yo		
Secukinumab (COSENTYX)	≥18 yo			≥18 yo	≥18 yo			
Tildrakizumab-asmn (ILUMYA)				≥18 yo				
Tocilizumab (ACTEMRA)			≥2 yo			≥18 yo		CRS ≥2 yo GCA ≥18 yo
Tofacitinib (XELJANZ)					≥18 yo	≥18 yo	≥18 yo	
Ustekinumab (STELARA)		≥18 yo		≥12 yo	≥18 yo			
Vedolizumab (ENTYVIO)		≥18 yo					≥18 yo	

Abbreviations: CLL = Chronic Lymphocytic Leukemia; CRS = Cytokine Release Syndrome; FCAS = Familial Cold Autoinflammatory Syndrome; FMF = Familial Mediterranean Fever; GCA = Giant Cell Arteritis; GPA = Granulomatosis with Polyangiitis (Wegener's Granulomatosis); HIDS: Hyperimmunoglobulin D Syndrome; MKD = Mevalonate Kinase Deficiency; MWS = Muckle-Wells Syndrome; NHL = Non-Hodgkin's Lymphoma; NOMID = Neonatal Onset Multi-Systemic Inflammatory Disease; TRAPS = Tumor Necrosis Factor Receptor Associated Periodic Syndrome; yo = years old.

Approval Criteria		
1. What diagnosis is being treated?	Record ICD-10 code.	
2. Is the diagnosis funded by OHP?	<b>Yes:</b> Go to #3	<b>No:</b> Pass to RPh. Deny; not funded by the OHP.
3. Is this a request for continuation of therapy?	<b>Yes:</b> Go to <b>Renewal Criteria</b>	<b>No:</b> Go to #4
4. Is the request for a non-preferred product and will the prescriber consider a change to a preferred product?  <u>Message:</u>  <ul style="list-style-type: none"> <li>Preferred products are reviewed for comparative effectiveness and safety by the Oregon Pharmacy and Therapeutics Committee.</li> </ul>	<b>Yes:</b> Inform prescriber of preferred alternatives.	<b>No:</b> Go to #5
5. Has the patient been annually screened for latent or active tuberculosis and if positive, started tuberculosis treatment?	<b>Yes:</b> Go to #6	<b>No:</b> Pass to RPh. Deny; medical appropriateness.  May approve for up to 3 months to allow time for screening.

## Approval Criteria

<p>6. Is the diagnosis Juvenile Idiopathic Arthritis, non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Non-infectious Posterior Uveitis, or one of the following syndromes:</p> <ul style="list-style-type: none"> <li>• Familial Cold Autoinflammatory Syndrome</li> <li>• Muckle-Wells Syndrome</li> <li>• Neonatal Onset Multi-Systemic Inflammatory Disease</li> <li>• Tumor Necrosis Factor Receptor Associated Periodic Syndrome</li> <li>• Hyperimmunoglobulin D Syndrome</li> <li>• Mevalonate Kinase Deficiency</li> <li>• Familial Mediterranean Fever</li> <li>• Giant Cell Arteritis</li> <li>• Cytokine Release Syndrome</li> </ul> <p>AND</p> <p>Is the request for a drug FDA-approved for one of these conditions as defined in Table 1?</p>	<p><b>Yes:</b> Approve for length of treatment.</p>	<p><b>No:</b> Go to #7</p>
<p>7. Is the diagnosis ankylosing spondylitis and the request for a drug FDA-approved for this condition as defined in Table 1?</p>	<p><b>Yes:</b> Go to #8</p>	<p><b>No:</b> Go to #9</p>
<p>8. If the request is for a non-preferred agent, has the patient failed to respond or had inadequate response to a Humira® product or an Enbrel® product after a trial of at least 3 months?</p>	<p><b>Yes:</b> Approve for up to 6 months. Document therapy with dates.</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p>
<p>9. Is the diagnosis plaque psoriasis and the request for a drug FDA-approved for this condition as defined in Table 1?</p> <p>Note: Only treatment for <i>severe</i> plaque psoriasis is funded by the OHP.</p>	<p><b>Yes:</b> Go to #10</p>	<p><b>No:</b> Go to #12</p>

## Approval Criteria

<p>10. Is the plaque psoriasis severe in nature, which has resulted in functional impairment (e.g., inability to use hands or feet for activities of daily living, or significant facial involvement preventing normal social interaction) <u>and</u> one or more of the following:</p> <ul style="list-style-type: none"> <li>• At least 10% body surface area involvement; <u>or</u></li> <li>• Hand, foot or mucous membrane involvement?</li> </ul>	<p><b>Yes:</b> Go to #11</p>	<p><b>No:</b> Pass to RPh. Deny; not funded by the OHP.</p>
<p>11. Has the patient failed to respond or had inadequate response to each of the following first-line treatments:</p> <ul style="list-style-type: none"> <li>• Topical high potency corticosteroid (e.g., betamethasone dipropionate 0.05%, clobetasol propionate 0.05%, fluocinonide 0.05%, halcinonide 0.1%, halobetasol propionate 0.05%; <u>and</u> triamcinolone 0.5%); <u>and</u></li> <li>• At least one other topical agent: calcipotriene, tazarotene, anthralin; <u>and</u></li> <li>• Phototherapy; <u>and</u></li> <li>• At least one other systemic therapy: acitretin, cyclosporine, or methotrexate; <u>and</u></li> <li>• One biologic agent: either a Humira<sup>®</sup> product or an Enbrel<sup>®</sup> product for at least 3 months?</li> </ul>	<p><b>Yes:</b> Approve for up to 6 months.</p> <p>Document each therapy with dates.</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p>
<p>12. Is the diagnosis rheumatoid arthritis or psoriatic arthritis and the request for a drug FDA-approved for these conditions as defined in Table 1?</p>	<p><b>Yes:</b> Go to #13</p>	<p><b>No:</b> Go to #17</p>

## Approval Criteria

<p>13. Has the patient failed to respond or had inadequate response to at least one of the following medications:</p> <ul style="list-style-type: none"> <li>• Methotrexate, leflunomide, sulfasalazine or hydroxychloroquine for <math>\geq 6</math> months; <u>or</u></li> <li>• Have a documented intolerance or contraindication to disease-modifying antirheumatic drugs (DMARDs)? AND</li> <li>• Had treatment failure with at least one biologic agent: a Humira<sup>®</sup> product or an Enbrel<sup>®</sup> product for at least 3 months?</li> </ul>	<p><b>Yes:</b> Go to #14</p> <p>Document each therapy with dates.</p> <p>If applicable, document intolerance or contraindication(s).</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p>
<p>14. Is the request for tofacitinib?</p>	<p><b>Yes:</b> Go to #16</p>	<p><b>No:</b> Go to #15</p>
<p>15. Is the patient on concurrent DMARD therapy with plans to continue concomitant use OR does the patient have documented intolerance or contraindication to DMARDs?</p>	<p><b>Yes:</b> Approve for up to 6 months.</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p> <p>Biologic therapy is recommended in combination with DMARDs (e.g. methotrexate) for those who have had inadequate response with DMARDs.</p>
<p>16. Is the patient currently on other biologic therapy or on a potent immunosuppressant like azathioprine, tacrolimus or cyclosporine?</p> <p><u>Note:</u> Tofacitinib may be used concurrently with methotrexate or other oral DMARD drugs.</p>	<p><b>Yes:</b> Pass to RPh. Deny; medical appropriateness.</p>	<p><b>No:</b> Approve for up to 6 months at a maximum dose of 10 or 11 mg daily for Rheumatoid Arthritis OR</p> <p>10 mg twice daily for 8 weeks then 5 or 10 mg twice daily for Ulcerative Colitis</p>

Approval Criteria		
17. Is the diagnosis Crohn's disease or ulcerative colitis and the request for a drug FDA-approved for these conditions as defined in Table 1?	<b>Yes:</b> Go to #18	<b>No:</b> Go to #19
18. Has the patient failed to respond or had inadequate response to at least one of the following conventional immunosuppressive therapies for ≥6 months: <ul style="list-style-type: none"> <li>• Mercaptopurine, azathioprine, or budesonide; <u>or</u></li> <li>• Have a documented intolerance or contraindication to conventional therapy?</li> </ul> <b>AND</b> <ul style="list-style-type: none"> <li>• Has the patient tried and failed a 3 month trial of a Humira® product?</li> </ul>	<b>Yes:</b> Approve for up to 12 months.  Document each therapy with dates.  If applicable, document intolerance or contraindication(s).	<b>No:</b> Pass to RPh. Deny; medical appropriateness.
19. Is the diagnosis Granulomatosis with Polyangiitis or Microscopic Polyangiitis and the requested drug rituximab for <i>induction or maintenance</i> of remission?	<b>Yes:</b> Approve for length of treatment.	<b>No:</b> Pass to RPh. Deny; medical appropriateness.

Renewal Criteria		
1. Is the request for treatment of psoriatic arthritis or rheumatoid arthritis?	<b>Yes:</b> Go to #2	<b>No:</b> Go to #3
2. Has the patient been adherent to both biologic and DMARD therapy?	<b>Yes:</b> Go to #3	<b>No:</b> Pass to RPh. Deny; medical appropriateness.
3. Has the patient's condition improved as assessed by the prescribing provider and provider attests to patient's improvement.	<b>Yes:</b> Approve for 6 months.  Document baseline assessment and provider attestation received.	<b>No:</b> Pass to RPh; Deny; medical appropriateness.